Literature DB >> 27915995

Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.

Sascha Bruckmann1, Anja Brenn1, Markus Grube2, Katharina Niedrig3, Silva Holtfreter4, Oliver von Bohlen und Halbach3, Martin Groschup5, Markus Keller5, Silke Vogelgesang1.   

Abstract

BACKGROUND: Immunization against beta-amyloid (Aβ) reduces cerebral Aβ deposits and improves cognitive capacities in transgenic mouse models, and thus has been considered a promising disease- modifying therapeutic approach for Alzheimer's disease (AD). Although clinical trials in AD patients have yielded evidence for clearance of parenchymal Aβ plaques, Aβ increases in blood vessels of treated patients. We hypothesize that an age-related decline in the mechanisms that clear Aβ from the brain might be at least in part responsible for the failure to purge and re-distribute Aβ. The expulsion of Aβ via the blood-brain barrier is mediated by specialized transport proteins such as P-glycoprotein (P-gp, ABCB1/MDR1).
OBJECTIVE: The objective of this study is to investigate the influence of the absence of P-gp at the bloodbrain barrier on the effectiveness of Aβ peptide immunization in APP/PS1+/- P-gp ko mice.
METHODS: Male APP/PS1+/- P-gp wt (n = 8) and APP/PS1+/- P-gp ko (n = 8) mice were actively immunized with human Aβ42. After behavioral testing animals were sacrificed at the age of 395 days (+/- 5 days) and antibody titres against Aβ were measured. Brains were dissected and soluble/insoluble cerebral Aβ was quantified, additionally the number of amyloid plaques and severity of amyloid angiopathy were evaluated.
RESULTS: In immunized mice with intact P-gp, our results showed a significant reduction of soluble and insoluble Aβ40 and Aβ42. Furthermore, immunization significantly reduced Aβ plaque burden. In contrast, immunized APP/PS1+/- P-gp ko mice lacking functional P-gp did not show a reduction of Aβ40 or Aβ42 accumulation in the brain except for the soluble form of Aβ42. Furthermore, after active immunization these mice displayed a stronger intracerebral amyloid angiopathy.
CONCLUSION: The results show that the absence of P-gp results in a significant disturbance of Aβ removal from the brain and increased intraparenchymal cerebral amyloid angiopathy after immunization against Aβ. Our data indicate that the selective up-regulation of P-gp could enhance the efficacy of Aβ immunization in the treatment or prevention of AD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Active immunization; Alzheimer's disease; Pglycoprotein; amyloid angiopathy; beta-amyloid; blood-brain-barrier; clearance

Mesh:

Substances:

Year:  2017        PMID: 27915995     DOI: 10.2174/1567205013666161201201227

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  8 in total

1.  Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Olaia Martínez-Iglesias; Lola Corzo; Natalia Cacabelos; Rocío Pego; Juan C Carril
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier.

Authors:  Stephen B Hladky; Margery A Barrand
Journal:  Fluids Barriers CNS       Date:  2018-10-19

3.  Neuronal Activity Regulates Blood-Brain Barrier Efflux Transport through Endothelial Circadian Genes.

Authors:  Robert S Pulido; Roeben N Munji; Tamara C Chan; Clare R Quirk; Geoffrey A Weiner; Benjamin D Weger; Meghan J Rossi; Sara Elmsaouri; Mario Malfavon; Aaron Deng; Caterina P Profaci; Marie Blanchette; Tongcheng Qian; Koji L Foreman; Eric V Shusta; Michael R Gorman; Frédéric Gachon; Stefan Leutgeb; Richard Daneman
Journal:  Neuron       Date:  2020-09-25       Impact factor: 17.173

Review 4.  P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer's Disease.

Authors:  Giulia Sita; Patrizia Hrelia; Andrea Tarozzi; Fabiana Morroni
Journal:  Oxid Med Cell Longev       Date:  2017-11-26       Impact factor: 6.543

5.  Modulation of the ATP-Binding Cassette B1 Transporter by Neuro-Inflammatory Cytokines: Role in the Pathogenesis of Alzheimer's Disease.

Authors:  Fawaz Alasmari; Charles R Ashby; Frank S Hall; Youssef Sari; Amit K Tiwari
Journal:  Front Pharmacol       Date:  2018-06-20       Impact factor: 5.810

Review 6.  Mamma Mia, P-glycoprotein binds again.

Authors:  Richard Callaghan; Ingrid C Gelissen; Anthony M George; Anika M S Hartz
Journal:  FEBS Lett       Date:  2020-10-20       Impact factor: 4.124

Review 7.  The emerging risk of exposure to air pollution on cognitive decline and Alzheimer's disease - Evidence from epidemiological and animal studies.

Authors:  Jason Kilian; Masashi Kitazawa
Journal:  Biomed J       Date:  2018-07-17       Impact factor: 4.910

8.  Protecting P-glycoprotein at the blood-brain barrier from degradation in an Alzheimer's disease mouse model.

Authors:  Yujie Ding; Yu Zhong; Andrea Baldeshwiler; Erin L Abner; Björn Bauer; Anika M S Hartz
Journal:  Fluids Barriers CNS       Date:  2021-03-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.